certolizumab pegol vs infliximab-dyyb (Zymfentra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Crohn's DiseasePEGylated anti-TNF Fab' fragment
Weak signal

NCT00552344 · Phase 3 · completed

This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)

Result source: NCT00552058

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03945019 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.

Next expected readout: December 2026 · NCT06064864 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcertolizumab pegolinfliximab-dyyb (Zymfentra)
Clinical remission (induction)31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058
—Not reported
Endoscopic response (induction)—Not posted · NCT00152425—Not reported
Clinical remission (maintenance)37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408
—Not reported
Endoscopic response (maintenance)—Not posted · NCT00152425—Not reported

Clinical remission (induction)

certolizumab pegol
31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (induction)

certolizumab pegol
—Not posted · NCT00152425
infliximab-dyyb (Zymfentra)
—Not reported

Clinical remission (maintenance)

certolizumab pegol
37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (maintenance)

certolizumab pegol
—Not posted · NCT00152425
infliximab-dyyb (Zymfentra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. certolizumab pegol: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegol
Dropout rate
78.4%a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
80.3%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
69.5%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
92.3%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
7.2%
NCT00552058 · Phase 3 · monotherapy
40.4%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
46.2%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
53.3%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
25%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
3.1%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
35.8%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
18.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
51%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
3.6%
NCT00552058 · Phase 3 · monotherapy
14.6%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
—400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
—400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
12.5%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
37.1%a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
40.3%
NCT00160524 · Phase 3 · monotherapy
13.4%400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
13.4%400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
31.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
44.5%
NCT00160706 · Phase 3 · monotherapy
14.6%400 mg
NCT00356408 · Phase 3 · monotherapy
0%CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
12.1%CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
5.4%
NCT00552058 · Phase 3 · monotherapy
38.2%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
40%High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
0%Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
50%Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
23.1%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
33.3%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
31.3%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
9.4%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
crohn's disease 31.6%
abdominal pain 18.7%
upper respiratory tract infection 15.7%
NCT00552344 · Phase 3 · monotherapy
show 21 more results
crohn's disease 21.8%
nasopharyngitis 15.3%
abdominal pain 15%
NCT00160524 · Phase 3 · monotherapy
400 mg every 2 weeks
nasopharyngitis 17.2%
pyrexia 11.8%
arthralgia 10.8%
NCT00308581 · Phase 3 · monotherapy
400 mg every 4 weeks
headache 16.6%
nasopharyngitis 12.3%
nausea 11.2%
NCT00308581 · Phase 3 · monotherapy
400 mg
nasopharyngitis 27.5%
headache 20.5%
pyrexia 20.5%
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 34.5%
abdominal pain 20%
arthralgia 15.8%
NCT00160706 · Phase 3 · monotherapy
400 mg
crohn's disease 21.4% (placebo 7.1%)
arthralgia 18.4% (placebo 0%)
upper respiratory tract infection 13.6% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
arthralgia 25% (placebo 0%)
myalgia 18.8% (placebo 0%)
sinusitis 18.8% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
crohn's disease 33.3% (placebo 7.1%)
arthralgia 21.2% (placebo 0%)
nausea 18.2% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
headache 5.4% (placebo 4.7%)
abdominal pain 4.5% (placebo 3.7%)
arthralgia 4% (placebo 2.8%)
NCT00552058 · Phase 3 · monotherapy
400 mg
headache 33.7%
arthralgia 30.3%
nasopharyngitis 23.6%
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
High-dose (Weight Adjusted)
abdominal pain upper 40%
nasopharyngitis 20%
nausea 20%
NCT01190410 · Phase 2 · registry result, not featured evidence
Low-dose (Weight Adjusted)
asthma exercise induced 25%
cough 25%
dizziness 25%
NCT01190410 · Phase 2 · registry result, not featured evidence
Re-Induction
abdominal injury 50%
anal fissure 50%
c-reactive protein increased 50%
NCT01190410 · Phase 2 · registry result, not featured evidence
400 mg / 200 mg
pyrexia 46.2% (placebo 11.1%)
nasopharyngitis 38.5% (placebo 55.6%)
contusion 15.4% (placebo 0%)
NCT00329420 · Phase 2 · registry result, not featured evidence
400 mg / 400 mg
nasopharyngitis 40% (placebo 55.6%)
pyrexia 20% (placebo 11.1%)
nausea 13.3% (placebo 5.6%)
NCT00329420 · Phase 2 · registry result, not featured evidence
nasopharyngitis 20% (placebo 22.2%)
nausea 13.3% (placebo 22.2%)
urinary tract infection 13.3% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
nasopharyngitis 62.5% (placebo 22.2%)
dna antibody positive 12.5% (placebo 22.2%)
headache 12.5% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
400 mg
nasopharyngitis 21.9% (placebo 31.3%)
nausea 6.3% (placebo 3.1%)
pharynx discomfort 6.3% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 23.3% (placebo 31.3%)
nausea 6.7% (placebo 3.1%)
pharyngolaryngeal pain 6.7% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

Clinical Remission 46.1% (n=89) @ 10wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
27% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
54.7% (n=592) @ 364wk
NCT00160524 · Phase 3 · monotherapy
HBI 21.7% (n=594) @ 364wk
responder rate · % of participants
No placebo or comparator arm
NCT00160524 · Phase 3 · monotherapy
show 2 more results
52.8% (n=307) @ 362wk
NCT00160706 · Phase 3 · monotherapy
65.6% (n=299) @ 362wk
NCT00160706 · Phase 3 · monotherapy
CDAI-100 37.4% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 70 participants as posted
show 1 more result
35.5% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 66 participants as posted
CDAI-70 40.1% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
show 1 more result
40.3% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
Clinical Remission 27.3% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 51 participants as posted
show 1 more result
28% (n=186) @ 26wk*400 mg every 2 weeks
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 52 participants as posted
CDAI 175.62 score @ 8wk400 mg every 4 weeks
absolute value · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
169.18 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
164.65 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
162.86 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
173.83 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
163.78 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.34 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
158.68 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
163.73 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.05 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
153.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.64 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.79 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
138.6 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
128.13 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
141.89 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
135.49 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
139.5 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
122.37 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
131.41 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
CDAI -133.35 score @ 8wk400 mg every 4 weeks
absolute change · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
-137.7 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.16 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.26 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-134.51 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.17 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.54 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.08 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-141.9 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.89 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-150.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.66 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-139.98 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-162.85 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-171.52 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-159.13 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-165.06 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-160.44 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-176.85 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-168.59 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
Duration of Response 4.21 months400 mg every 4 weeks
time to event · months
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to months from 128 days as posted
show 1 more result
4.11 months*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to months from 125 days as posted
Steroid-free Remission 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
3.9% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
3.9% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
3.8% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
6.6% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.3% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9.2% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
9% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
10.5% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
7.7% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
10.5% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
6.4% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
Steroid Free 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
5.3% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
6.6% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
6.4% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
12.8% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
11.8% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
11.8% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
9% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
14.5% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 11 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
13.2% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
7.7% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
Maintenance of 61.8% (n=166)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
CDAI 53.3% (n=229)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
50.6% (n=89) @ 10wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
32.6% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3

+ 28 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · infliximab-dyyb (Zymfentra)'s landscape